Heat-resistant wax matrix particles for enzyme encapsulation
阅读说明：本技术 用于酶包封的耐热蜡基质颗粒 (Heat-resistant wax matrix particles for enzyme encapsulation ) 是由 P·莫斯莱米 N·T·贝克尔 L·巴尔纳德 于 2018-02-08 设计创作，主要内容包括：描述了涉及用于酶包封的耐热蜡基质颗粒的组合物和方法。所述颗粒非常适合用于动物饲料应用、特别是涉及蒸汽造粒的那些。(Compositions and methods relating to thermostable wax matrix particles for enzyme encapsulation are described. The granules are well suited for use in animal feed applications, particularly those involving steam granulation.)
1. A granule comprising microparticles containing one or more enzymes dispersed within a high melting wax matrix.
2. The particle of claim 1, wherein the wax matrix comprises a water-insoluble wax.
3. The particle of claim 1 or 2, wherein the wax has a peak maximum melting point of greater than 100 ℃, optionally greater than 110 ℃, and even optionally greater than 120 ℃.
4. The particle of any of claims 1-3, wherein the wax has an initial melting point of at least 100 ℃ and a peak maximum melting point of at least 110 ℃.
5. The particle of any of claims 1-3, wherein the wax has an initial melting point of at least 110 ℃ and a peak maximum melting point of at least 120 ℃.
6. The particle of any of claims 1-5, wherein the wax has a melt viscosity of less than 500 centipoise at a temperature within 25 ℃ above the wax melting temperature.
7. The particle of any of claims 1-5, wherein the wax has a weight average molecular weight of less than 3,000 and a polydispersity index of less than 3.
8. The particle of any one of claims 1-5, wherein ECR(40,140)Less than 20%, and preferably less than 15%.
9. The granule of any of claims 1-8, wherein the enzyme is at least one of an amylase, a cellulase, a phytase, a protease, or a xylanase.
10. The granule of any one of claims 1-9 comprising an active enzyme payload of greater than 5% wt/wt and a water activity of less than 0.3.
11. The granule of any of claims 1-10, wherein the enzyme microparticles range from about 1 to about 250 microns.
12. The particle of any one of claims 1-10, comprising a water content of less than 5% wt/wt and a water activity of less than 0.4.
13. The particle of any one of claims 1-12, wherein the particle ranges from about 100 to about 500 microns.
14. The particle of claim 13, wherein the particle size ranges from about 212 to about 425 microns.
15. The particle of claim 13, wherein the particle size ranges from about 212 to about 300 microns.
16. The granule of any of claims 1-15, wherein the enzyme microparticles are produced by any of spray drying, spray freezing, dry granulation, wet granulation or fluid bed granulation.
17. The particle of any one of claims 1-16, comprising a filler component selected from the group of minerals consisting of limestone, mica, clay, and titanium oxide.
18. The particles of any of claims 1-17, wherein the wax is selected from the group of polymeric waxes consisting of polyethylene wax, oxidized polyethylene wax, polypropylene wax, fischer-tropsch wax, carboxylate waxes, or mixtures thereof.
19. The particle of any of claims 1-17, wherein the wax is a polyethylene wax.
20. Granules according to any of claims 1 to 17, wherein the wax is selected from the group of waxes consisting of aluminium stearate, calcium stearate, magnesium stearate, zinc behenate, zinc laurate, zinc stearate or mixtures thereof.
21. The particle of any of claims 1-17, wherein the wax is zinc stearate.
22. The particle of any of claims 18-21, wherein the particle comprises a polyterpene resin, a rosin resin, a dammar resin, or a mixture of said resins.
23. The particle of claim 21, wherein the particle comprises a polyterpene resin, a rosin resin, a dammar resin, or a mixture of said resins.
24. A method for preparing granules comprising enzyme microparticles dispersed within a high melting wax matrix, the method comprising:
(d) dispersing a dry enzyme powder in a molten wax to provide an enzyme-wax suspension;
(e) atomizing the enzyme-wax suspension to form discrete droplets; and
(f) the enzyme-wax particles were cooled, solidified and collected.
25. The method of claim 24, wherein the resulting enzyme-wax particle is a particle according to any one of claims 1-23.
26. A method for improving growth of poultry or pigs, the method comprising introducing the particle of any of claims 1-23 into the diet of the animal and measuring the improvement in growth relative to a control animal not treated with such particle.
Technical Field
The compositions and methods of the present invention relate to thermostable wax matrix particles for enzyme encapsulation. The granules are well suited for use in animal feed applications, particularly those involving steam granulation.
Background
Current commercial processes for producing granules include granulation, high shear granulation and fluid bed spraying. Granulation of enzyme granules is described in U.S. Pat. No. 4,016,040. In granulation (also known as spray freezing or spray freezing), a molten liquid is atomized and then solidified into granules. Various atomization methods may be used, including spray nozzle atomization, centrifugal nozzle atomization, and rotary disk atomization. (see, e.g., U.S. patent nos. 7,261,529 and 7,758,778). When granulation is applied for enzyme encapsulation, a dry enzyme powder is blended with a molten hydrophilic binder such as a non-ionic surfactant and the mixture is atomized into droplets into cold air using a spray nozzle or disk such that it solidifies into substantially spherical, water-dispersible solid particles or "small particles" containing the dispersed enzyme powder. The binder in these small particles is hydrophilic and water soluble or dispersible, allowing the release of the enzyme into the detergent wash water once the binder is dissolved.
High shear granulation of enzymes suitable for use in granulated animal feed is described, for example, in WO 92/12645. The enzyme is first granulated with various binders and fillers, for example to produce so-called "T-granules" (described in U.S. Pat. No. 4,106,991). The T-fines are then overcoated with an agent comprising a high melting point fat or wax, typically also further comprising an inorganic filler such as kaolin, magnesium silicate or calcium carbonate. The high melting point fat or wax is specified as a glyceride or other waxy substance having a melting point between 30 ℃ and 100 ℃.
Enzyme granules having multiple protective coatings can be produced using a coating process such as fluid bed spraying. For example, U.S.2006/040394 describes a method for producing granules that are stable to steam granulation, including a moisture hydrating coating and a moisture barrier layer (applied on the enzyme core). The moisture hydrating coating may be a layer comprising sodium sulfate and the moisture barrier layer may be a layer comprising polyvinyl alcohol and talc.
A method for protecting enzyme granules with a thick coating is described in WO 01/25412. The coating is referred to as "shell element" which is applied on the "core element" such that the ratio between the diameter of the resulting granules and the diameter of the core element is at least 1.1. Enzyme activity is limited to the nuclear unit; the shell units are designated as "substantially enzyme free", that is, containing less than 5mg enzyme per gram shell. The shell unit has no specified limit on its chemical composition, and may contain a hydrophilic or hydrophobic material, such as a polymer or wax. When used to protect enzymes in the case of steam pelleted feed, it is specified that the shell unit should have an overall composition that will melt under the pelleted conditions, and should have a melting temperature of 70 ℃ to 120 ℃.
Although the methods and formulations described in the above-cited patents provide some degree of protection for enzymes against inactivation by high temperatures and moisture (as encountered in steam pelleting or storage of animal feed or detergents), these techniques have certain drawbacks. In previous granulation applications, the binder used in the matrix will dissolve or will melt under high temperature and humidity conditions (such as those used in steam granulation or spray drying laundry detergents), making the enzyme very susceptible to denaturation by hot steam or water. In the case of the other techniques cited, the protection of the enzyme requires the addition of a thick coating substantially free of enzyme. Such coatings can be easily applied to larger enzyme cores (i.e., those having a median diameter greater than about 300 microns), but they cannot be effectively applied to smaller particles.
Accordingly, it would be desirable to identify a granulation technique that can protect enzymes against high temperatures and moisture, provide adequate release or bioavailability in aqueous-based applications (such as animal feed or detergents), and yet avoid the need to apply a protective coating or barrier. There is also a need for a granulation technique that is capable of producing granules with a high active enzyme concentration of less than 500 microns in diameter, providing both low cost and improved distribution when incorporated into a final product such as animal feed or detergents.
Disclosure of Invention
The compositions and methods of the present invention relate to thermostable wax matrix particles for enzyme encapsulation. The wax matrix granules are well suited for use in food and animal feed applications, particularly those involving steam granulation. Aspects and examples of the compositions and methods are described in the following independently numbered paragraphs.
1. In one aspect, a granule is provided comprising microparticles containing one or more enzymes dispersed within a high melting wax matrix.
2. In some embodiments of the particles of paragraph 1, the wax matrix comprises a water-insoluble wax.
3. In some embodiments of the particles of
4. In some embodiments of the particles of any of paragraphs 1-3, the wax has an initial melting point of at least 100 ℃ and a peak maximum melting point of at least 110 ℃.
5. In some embodiments of the particles of any of paragraphs 1-3, the wax has an initial melting point of at least 110 ℃ and a peak maximum melting point of at least 120 ℃.
6. In some embodiments of the particles of any of paragraphs 1-5, the wax has a melt viscosity of less than 500 centipoise at a temperature within 25 ℃ above the wax melting temperature.
7. In some embodiments of the particles of any of paragraphs 1-5, the wax has a weight average molecular weight of less than 3,000 and a polydispersity index of less than 3.
8. In some embodiments of the particles of any of paragraphs 1-5, the ECR(40,140)Less than 20%, and preferably less than 15%.
9. In some embodiments of the granule according to any of paragraphs 1-8, the enzyme is at least one of an amylase, a cellulase, a phytase, a protease, or a xylanase.
10. In some embodiments, the particle according to any of paragraphs 1-9 comprises an active enzyme payload of greater than 5% wt/wt and a water activity of less than 0.3.
11. In some embodiments of the granule of any of paragraphs 1-10, the enzyme microparticles range from about 1 to about 250 microns.
12. In some embodiments, the particle of any of paragraphs 1-10 comprises a water content of less than 5% wt/wt and a water activity of less than 0.4.
13. In some embodiments of the particle of any of paragraphs 1-12, the particle ranges from about 100 to about 500 microns.
14. In some embodiments of the particles of paragraph 13, the particle size ranges from about 212 to about 425 microns.
15. In some embodiments of the particles of paragraph 13, the particle size ranges from about 212 to about 300 microns.
16. In some embodiments of the granule according to any of paragraphs 1-15, the enzyme microparticles are produced using any of spray drying, spray freezing, dry granulation, wet granulation, or fluid bed granulation.
17. In some embodiments, the particles according to any of paragraphs 1-16 comprise a filler component selected from the group of minerals consisting of limestone, mica, clay, and titanium oxide.
18. In some embodiments of the particles according to any of paragraphs 1-17, the wax is selected from the group of polymeric waxes consisting of polyethylene waxes, oxidized polyethylene waxes, polypropylene waxes, Fischer-Tropsch (Fischer-Tropsch) waxes, carboxylate waxes, or mixtures thereof.
19. In some embodiments of the particles of any of paragraphs 1-17, the wax is a polyethylene wax.
20. In some embodiments of the granules of any of paragraphs 1-17, the wax is selected from the group of waxes consisting of aluminum stearate, calcium stearate, magnesium stearate, zinc behenate, zinc laurate, zinc stearate, or mixtures thereof.
21. In some embodiments of the particles according to any of paragraphs 1-17, the wax is zinc stearate.
22. In some embodiments of the particles of any of paragraphs 18-21, the particles comprise polyterpene resins, rosin resins, dammar resins, or mixtures of the resins.
23. In some embodiments of the particle of paragraph 21, the particle comprises a polyterpene resin, a rosin resin, a dammar resin, or a mixture of said resins.
24. In another aspect, there is provided a method for preparing a granule comprising enzyme microparticles dispersed within a high melting wax matrix, the method comprising:
(a) dispersing a dry enzyme powder in a molten wax to provide an enzyme-wax suspension;
(b) atomizing the enzyme-wax suspension to form discrete droplets; and
(c) the enzyme-wax particles were cooled, solidified and collected.
25. In some embodiments of the method of
26. In another aspect, there is provided a method for improving growth of poultry or pigs, the method comprising introducing a particle according to any of paragraphs 1-23 into the diet (diet) of the animal and measuring the improvement in growth relative to a control animal not treated with such particle.
These and other aspects and embodiments of the compositions and methods will be apparent from the description and drawings.
Drawings
FIG. 1 shows a DSC thermogram of commercial stearic acid, indicating ECR(40,140)＝99.69％。
FIG. 2 shows the DSC thermogram of commercial Fischer-Tropsch wax (Sasolwax C105) indicating ECR(40,140)The content was 45.94%.
FIG. 3 shows a commercial polyethylene homopolymer wax (Honeywell A-820A) DSC thermogram of (1), indicating ECR(40,140)Is 15.26 percent
FIG. 4 shows commercial zinc stearate (C)SP VEG) DSC thermogram showing ECR(40,140)The content was 9.68%.
FIG. 5 shows a commercial polyethylene homopolymerWax (POLYWAX)TM2000) DSC thermogram of (1), indicating ECR(40,140)The content was 6.07%.
FIG. 6 is a schematic illustration of a rotary disc atomization arrangement for producing enzyme granules. The enzyme payload and temperature values shown are exemplary.
Fig. 7 is a graph showing the change in tibial epiphyseal ash (epiphyseal tiaash) measured in a feed phytase bioefficacy study. The phytase granules tested were polyethylene wax microencapsulated phytase granules P75.1M and P75.4M. Commercial DaniscoPHY product fines served as a control.
Fig. 8 is a graph showing the variation of total tibial ash measured in a feed phytase bioefficacy study using the same granules as in fig. 7.
Fig. 9 is a graph showing the change in phalangeal ash (toe ash) measured in a feed phytase bioefficacy study using the same granules as in fig. 7.
Fig. 10 is a graph showing the variation of tibial epiphyseal ash measured in a feed phytase bioefficacy study using the same granules as in fig. 7.
Fig. 11 is a graph showing the variation of total tibial ash measured in a feed phytase bioefficacy study using the same granules as in fig. 7.
Fig. 12 is a graph showing changes in phalangeal ash measured in a feed phytase bioefficacy study using the same granules as in fig. 7.
Fig. 13 is a graph showing the variation of tibial epiphyseal ash measured in a feed phytase bioefficacy study. The phytase granules tested were polyethylene wax microencapsulated phytase granules P75.1M and P96.5. Commercial Danisco
Fig. 14 is a graph showing the change in total tibial ash measured in a feed phytase bioefficacy study using the same granules as in fig. 13.
Fig. 15 is a graph showing changes in phalanx ash with measured feed phytase activity in bioefficacy studies using the same granules as in fig. 13.
Fig. 16 is a graph showing the change in apparent total digestive tract digestibility% (ATTD P%) of P measured in a feed phytase bioefficacy study using the same granules as in fig. 7.
Detailed Description
I. introduction-Heat-resistant wax matrix particles
The compositions and methods of the present invention relate to protecting enzymes against inactivation under high temperature and high humidity conditions by encapsulating the enzymes within particles comprising a high melting wax matrix. The resulting thermotolerant wax matrix particles (referred to herein as "TRWMPs") are substantially spherical microparticles without a coating, the microparticles having an average diameter of less than about 500 microns and containing active enzyme in a payload of greater than 5% w/w. In some embodiments, the encapsulated enzyme retains 70% of the original enzyme activity when exposed to a temperature of 95 ℃ for 30 seconds in a typical animal feed pelleting process, and can provide acceptable enzyme bioavailability when incorporated into animal feed. In some embodiments, the granules provide acceptable enzyme bioavailability in food, animal feed, and other agricultural applications.
Definitions and abbreviations II
As used herein, a "wax" is defined as any hydrocarbon, fatty acid, fatty alcohol, or salt or ester thereof, which is insoluble in water but soluble in a non-polar organic solvent. A comprehensive definition of waxes has been established in Europe by Deutsche Gesellschaft fur Fettwissenschaft (DGF, German Fat Science Association for Fat Science). According to this definition, the wax (i) has a dropping or melting point of above 40 ℃. (ii) Melting without decomposition; (iii) has a melt viscosity of not more than 10,000mPa · s at 10 ℃ above the melting point; (iv) exhibits a strong negative temperature dependence in terms of viscosity and does not tend to stringiness above the melting point (stringiness); (v) polishable under slight pressure (politable) and has a strong temperature-dependent consistency and solubility; (vi) (vii) kneadable or difficult to break at 20 ℃, coarse to fine crystalline, transparent to opaque (but not glassy), or highly viscous or liquid, (vii) melts between 50 ℃ and 90 ℃ (as the particular waxes used in the compositions and methods of the invention melt at temperatures up to 200 ℃), and forms a paste or gel, and are poor conductors of heat and electricity (i.e., they are thermal and electrical insulators).
A wax is considered "water insoluble" if its equilibrium solubility in deionized water is less than 0.1% w/w. Waxes that are not water-insoluble are considered herein to be "water-soluble".
A wax is considered to be "low melting" if it has a peak maximum melting point below 100 ℃.
A wax is considered to be "high melting point" if it has a peak maximum melting point equal to or higher than 100 ℃, preferably higher than 110 ℃, and more preferably higher than 120 ℃.
As used herein, a "matrix" is a continuous solid phase surrounding a discontinuously dispersed solid. The substrate may be non-porous or porous. A matrix is "porous" if it has channels or pores that contain open void spaces or materials that can be at least partially dissolved or dispersed upon contact or immersion in water or aqueous solutions so as to allow water to penetrate, dissolve and extract the dispersed solids within the matrix.
As used herein, an "excipient" is an inactive component of a product that enhances product characteristics, e.g., handling, production, or storage stability, without affecting the activity or efficacy of the product. Although inactive with respect to efficacy, excipients provide beneficial features that allow the enzyme to be efficiently delivered to the target application.
Examples of excipients are "fillers" used to dilute the active ingredients to adjust efficacy or reduce formulation cost, "binders" to promote cohesion of formulation components or to increase the overall physical strength of the fine particles, "disintegrants" which swell on contact with water, aid in release of the active from the formulation, "glidants" to promote interparticle friction and powder flow through the processing equipment, "lubricants" to reduce friction and adhesion between formulation components and processing equipment, "preservatives" (e.g., moisture scavengers, free radical scavengers) to prevent or limit loss of enzyme activity by acting as stabilizing aids, and "absorbents" that preferentially absorb moisture to protect the fine particle's enzyme component.
As used herein, the term "bioavailability" refers to the availability of encapsulated enzymes to the intestinal tract of an animal when the animal ingests an animal feed product containing the encapsulated enzymes. In some embodiments, the term "bioavailability" refers to the availability of encapsulated enzymes for soil cleaning media in cleaning applications, such as laundry, dish, or hard surface cleaning.
The following abbreviations are used:
% w/w weight percent
Area under AUC heat flow curve
ATTD apparent Total digestive tract digestibility
avail available from avail
avg mean value
AvP available phosphorus
BW body weight
Ca calcium
cm
CP crude protein
Cys cysteine
d10Diameter of 10% of particles on cumulative volume-size distribution curve
d50Diameter of 50% of particles on cumulative volume-size distribution curve
d90Diameter of 90% of the particles on the cumulative volume-size distribution curve
dia diameter
DSC differential scanning calorimetry
dT/dT scan rate
ECR enthalpy change ratio
F-T Fischer-Tropsch
FTU Phytase Activity Unit
g
h hours
ISO International organization for standardization
kcal
kg kilogram
L liter
Lys lysine
m meter
m.p. melting Point
m3Cubic meter
Met methionine
MiMolecular weight of Polymer i
min for
min for
ml of
mol mole of
mm
MnNumber average molecular weight
mPa millipascal
MwMass average molecular weight
n number of
NC negative control
NiNumber of moles of Polymer having a molecular weight Mi
nm nanometer
non-phytate phosphate (non-phytate phosphate)
DEG C
PE polyethylene
Total uptake of Pin phosphorus
Pfo) Total fecal output of phosphorus
Px, Px.x applicants' internal formulation identifier
rpm revolutions per minute
s second
std dev standard deviation
T temperature
time t
Trp Tryptophan
vitals/TES vitamins and trace elements
wt/wt weight/weight
@ at … …
Micron diameter of
Micromole of mu mol
Waxes suitable for making TRWMP
Waxes suitable for use in the compositions and methods of the present invention may be naturally occurring and may be derived from non-fossil biological sources and include, but are not limited to: animal waxes such as beeswax, ganda beeswax, shellac wax, Chinese insect wax (Chinese insect wax), wool wax; vegetable waxes such as carnauba wax, candelilla wax, ouricury wax, sugarcane wax, Argentine Bonesia shrub wax (Retamo wax), and jojoba wax; long chain linear primary carboxylic acids derived from animal and vegetable fats, such as myristic acid, palmitic acid and stearic acid; a mixture of fatty acid derivatives; fatty acid salts such as aluminum stearate, calcium stearate, magnesium stearate and zinc stearate, zinc behenate and zinc laurate; and vegetable waxes, such as montan wax; or they may be derived from petroleum, such as macrocrystalline waxes (paraffin waxes) and microcrystalline waxes (microwaxes), or synthesized as small molecules (such as ethylene bis-stearamide) or as macromolecules, i.e. chemically polymerized from monomeric subunits, such as fischer-tropsch waxes or polyolefin waxes (including polyethylene waxes, polypropylene waxes and derivatives thereof).
Commercial examples of long chain carboxylic acids are fatty acid derivatives, e.g.A275 (ballocher GmbH)),
Examples of commercially available metal stearates include aluminum tri/distearate, such as(balhoh company), calcium stearate, e.g.(Halrohh Co.) and13-LD Ca stearate (Norac, Inc.), magnesium stearate, e.g., magnesium stearate
Commercial examples of zinc behenate and zinc laurate include
Ethylene bis-stearamideExamples of businesses includeL-AK (balhoh corporation),
Fischer-tropsch waxes are commercially available under different trade names, including ceraflur (BYK USA),(Shell/Baker Hughes, Inc.)),(Saxowax North America Ltd.) (
Polyethylene waxes are sold under several different trade names, including
Oxidized polyethylene waxes are commercially available under a variety of trade names, includingEO (Delshi corporation),PED (Kelaine corporation), PETROLITETM(Beckhols Co.) and(Innospec Leuna GmbH).
Polypropylene waxes are sold under several different trade names, including HI-WAXTM(Mitsui chemical Co.) and
In certain embodiments, the TRWMP may comprise natural, bio-based, or synthetic resins, including but not limited to rosin resins, polyterpene resins, and dammar resins.
The rosin resin is based on natural resources and,such as renewable pine stump wood (stumpwood). Refined and modified wood rosins are commercially available from Pinova, Inc under a variety of trade names, including FC、H and HA,
Polyterpene resins are based on natural and renewable raw materials including poly (alpha-pinene), poly (beta-pinene), poly (d-limonene), and mixtures thereof. Commercial examples of polyterpene resins include those offered under several trade names by pinova, including
Dammar resins are dry exudates from cultivated trees of kaureae species (Agathis spp.), rampart species (Hopea spp.), and/or buckeye species (horse spp). It consists of a complex mixture of acidic and neutral triterpenoid resins together with a polysaccharide material. Many triterpenes are low molecular weight compounds such as dammarane, dammarate acid (dammarenolic acid), oleanane, oleanolic acid, etc., but dammarate resins also contain a polymer fraction composed of polydipinene.
Suitable waxes include those having a peak maximum melting point, i.e., greater than 100 ℃, preferably greater than 110 ℃, and more preferably greater than 120 ℃. Unlike small molecules, the molecular weight of polymeric waxes is not a unique value. In contrast, a given polymer typically exhibits polydispersity, i.e., a molecular weight distribution, which depends on the manner in which the polymer is made. The distribution of molecular weights is generally represented by the average molecular weight. Polymer properties such as melting point are a function of molecular weight distribution and are therefore dependent on average molecular weight. Number average molecular weight (M) n) And mass average molecular weight (M)w) Defined by the following equation:
wherein N isiIs of molecular weight MiThe number of moles of the polymer (b).
The polymer waxes suitable for use in the compositions and methods of the present invention should have a mass average molecular weight (M) of between 1000 and 5000Da (g/mol), preferably between 1,800 and 4,800Da, and more preferably between 2000 and 3000Daw). The polymer waxes of the present invention should have a narrow molecular weight distribution, where the polydispersity index (M) isw/Mn) Less than 3, preferably less than 2, more preferably less than 1.5, and most preferably less than 1.2.
Waxes suitable for use in the compositions and methods of the present invention also have suitable Enthalpy Change Ratios (ECR) as defined below:
ECR(t0,tf)＝100％×AUC(t0,100)/AUC(t0,t)
wherein t is0And tfAre the initial and final scanning temperatures during differential scanning calorimetry (i.e., DSC thermogram), and AUC is the area under the DSC thermogram curve.
For example, ECR(40,140)Is the ratio of 100% multiplied by the area under the DSC thermogram between 40 ℃ and 100 ℃ to the area under the DSC thermogram between 40 ℃ and 140 ℃: ECR(40,140)＝100％×AUC(40,100)/AUC(40,140)。
ECR can be used as a metric for comparing the effectiveness of different wax materials for their potential protection during high temperatures, such as in animal feed pelleting. More specifically, ECR(40,140)Can be used as a low melting point hydrocarbon (m.p) in wax products. <An index of concentration at 100 ℃; lower amounts of lower melting hydrocarbons in the wax product correspond to smaller ECR(40,140)The value is obtained. Waxes suitable for use in the compositions and methods of the present invention may be characterized as having an ECR of less than 20%, preferably less than 15%, and more preferably less than 10%(40,140)Those of (a).
The examples of the present invention illustrate methods for determining ECR using fischer-tropsch (F-T) wax, Polyethylene (PE) wax, zinc stearate, and stearic acid, characterized using Differential Scanning Calorimetry (DSC).
For convenience, the characteristics of the particles of the invention are summarized in table 1.
TABLE 1 characterization of the particles of the invention
Characteristics of the particles
Preferred parameters
Peak maximum melting point
>100℃
Initial melting point of wax
≥100℃
Melt viscosity of wax
At a temperature within 25 ℃ above the melting temperature of the wax<500 centipoises
Average molecular weight of wax
<3,000
Wax polydispersity index
<3
Wax ECR(40,140)
<20％
Enzyme payload
>5％wt/wt
Water activity
<0.4
Water content
<5％wt/wt
Enzyme particle size range
1-500μm
Enzymes suitable for encapsulation in TRWMP
The compositions and methods of the invention are applicable to many different enzymes. Exemplary enzymes include acyltransferases, alpha-amylases, beta-amylases, alpha-galactosidases, arabinosidases, arylesterases, beta-galactosidases, carrageenases, catalases, cellobiohydrolases, cellulases, chondroitinases, cutinases, endo-beta-1, 4-glucanases, endo-beta-mannanases, esterases, exomannanases, galactanases, glucoamylases, hemicellulases, hyaluronidase, keratinases, laccases, lactases, ligninases, lipases, lipoxygenases, mannanases, oxidases, oxidoreductases, pectin lyases, pectin acetylesterases, pectinases, pentosanases, perhydrolases, peroxidases, peroxogenases, phenoloxidases, phosphatases, phospholipases, pentosanases, enzymes, alpha-galactosidases, arabinosidases, arylesterases, beta-galactosida, Phytase, polygalacturonase, protease, pullulanase, reductase, rhamnogalacturonase, beta-glucanase, tannase, transglutaminase, xylan acetyl esterase, xylanase, xyloglucanase, xylosidase, and combinations thereof.
Examples of phytases include, but are not limited to, those from Escherichia coli (Escherichia coli), Butterella sp, Citrobacter buchneri (Citrobacter braakii), Penicillium chrysosporium (Peniophoralcii) and Aspergillus niger (Aspergillus niger). In some embodiments, the protease is
Examples of proteases include, but are not limited to, subtilisins, such as those derived from Bacillus (Bacillus) (e.g., subtilisin, Bacillus lentus, Bacillus amyloliquefaciens, subtilisinThe enzymes Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168), including variants as described in, for example, U.S. patent nos. RE34,606, 5,955,340, 5,700,676, 6,312,936, and 6,482,628, which are all incorporated herein by reference. Additional proteases include trypsin (e.g., of porcine or bovine origin) and the Fusarium (Fusarium) protease described in WO 89/06270. In some embodiments, the protease is
Proteases include neutral metalloproteases, including those described in WO 07/044993 and WO 09/058661. Other exemplary metalloproteases include the recombinant form of the neutral metalloprotease nprE expressed in Bacillus subtilis (see, e.g., WO 07/044993) and the purified neutral metalloprotease PMN from Bacillus amyloliquefaciens (Bacillus amyloliquefaciens).
Lipases include, but are not limited to, Humicola lanuginosa (Humicola lanuginosa) lipase (see, e.g., EP 258068 and EP 305216); rhizomucor miehei (Rhizomucor miehei) lipase (see, e.g., EP 238023); candida lipases, such as Candida antarctica (C.antarctica) lipase (e.g., Candida antarctica lipase A or B; see, e.g., EP 214761); pseudomonas lipases, such as pseudomonas alcaligenes (p.alcaligenes) lipase and pseudomonas pseudoalcaligenes (p.pseudoalcaligenes) lipase (see, e.g., EP 218272); pseudomonas cepacia (p.cepacia) lipase (see, e.g., EP 331376); pseudomonas stutzeri (p.stutzeri) lipase (see, e.g., GB1,372,034); pseudomonas fluorescens (p.fluorescens) lipase; bacillus lipases (e.g., Bacillus subtilis lipase (Dartois et al (1993) biochem. Biophys. acta [ Proc. biochem. Biophys. ]1131: 253-260)), Bacillus stearothermophilus (B.stearothermophilus) lipase (see, e.g., JP 64/744992), and Bacillus pumilus (B.pumilus) lipase (see, e.g., WO 91/16422)).
Additional lipases include Penicillium camembertii (Penicillium camembertii) lipase (Yamaguchi et al (1991) Gene [ Gene ] ]103:61-67), Geotrichum candidum (Geotrichum candidum) lipase (see, Schimada et al (1989) J. biochem. [ J. Biochem.)]106:383-388) and various Rhizopus lipases (e.g.Rhizopus delemani (R.deleman) lipases (Hass et al (1991) Gene [ genes ]]109:117-Technology and biochemistry]56: 716-. Additional lipases are cutinases derived from Pseudomonas mendocina (see WO 88/09367) and from Fusarium solani (Fusarium solani pisi) (WO 90/09446). Various lipases are described in WO 11/111143, WO10/065455, WO 11/084412, WO 10/107560, WO 11/084417, WO 11/084599, WO11/150157, and WO 13/033318. In some embodiments, the LIPASE is M1LIPASETM、LUMA FASTTMAnd LIPOMAXTM(DuPont Industrial biosciences);andULTRA (novicent corporation); and LIPASE PTM"Amano" (one or more of Japan Pharmaceutical Co., Ltd.).
Amylases include, but are not limited to, those of bacterial or fungal origin, or even of mammalian origin. Many suitable are described in W09510603, WO9623873, WO0060, WO0114532, WO 9402597, WO0231124, WO0164852, WO2008092919, WO2005019443, WO2006031554, WO2011080352, WO2011076123, WO9826078, WO9710342, WO WO 2009149419, WO 2009061381, WO 2009100102, WO2010104675, WO 2010117511, WO 2010115021, WO 2013184577, WO 9418314, WO2008112459, WO 2013063460, WO 10115028, WO2009061380, WO 2009100102, WO2014099523, WO 2015077126A1, WO 2013184577, WO 2014164777, PCT/US 12/70334, PCT/US13/74282, PCT/CN 2013/077294, PCT/CN 2013/077134, PCT/CN 2013/077137, PCT/CN2013/077142, PCT/CN 2012/087135, PCT/US 12/62209, PCT/CN2013/084808, PCT/CN 2013/084809, and PCT/US 14/23458. Commercially available amylases include, but are not limited to STAINZYME
Cellulases include, but are not limited to, those having color care benefits (see, e.g., EP 0495257). Examples include Humicola insoles (Humicola insoles)lens) cellulase (see, e.g., U.S. Pat. No. 4,435,307), and commercially available cellulases, e.g.(Novitin Co.), and KAC-500(B)TM(Kao Corporation), and
Mannanases are described in U.S. Pat. nos. 6,566,114, 6,602,842, 5,476, and 775, 6,440,991, and U.S. patent application No. 61/739267, all of which are incorporated herein by reference in their entirety). Commercially available include, but are not limited to
in some embodiments, a peroxidase is used in combination with hydrogen peroxide or a source thereof (e.g., percarbonate, perborate, or persulfate) in a composition of the present teachings. In some alternative embodiments, the oxidase is used in combination with oxygen. Both types of enzymes are used for "solution bleaching" (i.e. to prevent the transfer of textile dyes from one dyed fabric to another when the fabrics are washed together in a wash liquor), preferably together with a synergist (see e.g. WO 94/12621 and WO 95/01426). Suitable peroxidases/oxidases include, but are not limited to, those of plant, bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments.
Perhydrolases include enzymes from Mycobacterium smegmatis (Mycobacterium smegmatis). Such enzymes, their enzymatic properties, their structures, and many variants and homologues thereof are described in detail in international patent application publications WO 05/056782A and WO 08/063400 a, and U.S. patent publications US 2008145353 and US 2007167344, which are incorporated by reference.
In some embodiments, the mycobacterium smegmatis perhydrolase, or homolog, comprises a S54V substitution.
Other perhydrolases include members of the carbohydrate family esterase family 7(CE-7 family), described, for example, in WO2007/070609 and U.S. patent application publication Nos. 2008/0176299, 2008/176783, and 2009/0005590. Members of the CE-7 family include cephalosporin C deacetylase (CAH; E.C.3.1.1.41) and acetylxylan esterase (AXE; E.C. 3.1.1.72). Members of the CE-7 esterase family share a conserved signature motif (Vincent et al, J.mol.biol. [ J.Mol. ],330:593-606 (2003)).
Other perhydrolases include those from Sinorhizobium meliloti (Sinorhizobium meliloti), Sinorhizobium meliloti (Mesorhizobium loti), Moraxella (Moraxella bovis), Agrobacterium tumefaciens (Agrobacterium tumefaciens), or rhizobium japonicum dejongeii (prothhecobacter dejongeii) (WO2005056782), pseudomonas mendocina (us patent No. 5,389,536), or pseudomonas putida (pseudomonas putida) (us patent nos. 5,030,240 and 5,108,457).
Preparation of trwmp
The encapsulation process requires first providing the enzyme in a substantially dry form as a powder. For example, the enzyme may be spray dried from an aqueous solution or suspension, or isolated as a precipitate by adding a salt, organic solvent or polymer to the enzyme solution. If the resulting powder precipitate contains water, it should be further dried in order to reduce the water content or water activity. The residual water content of the enzyme powder, including free water and bound water, should be less than 6%, preferably less than 5%, and more preferably less than 4%. The water activity (Aw) of the enzyme powder should be less than 0.3, preferably less than 0.2, and more preferably less than 0.1.
The spray-dried enzyme powder or precipitate may be further processed by dry or wet granulation, such as agglomeration, compaction or blending with other dry materials (including non-enzyme inactive excipients). In some embodiments, the enzyme solution may comprise a mixture of the enzyme concentrate and optionally additional excipients. The mixture may be further processed or granulated by methods such as spray agglomeration, spray granulation, low or high shear granulation, drum granulation, and the like.
The dried enzyme, alone or further mixed, processed or granulated as described above, along with optional water-soluble or water-insoluble fillers, pore formers, buffers, stabilizers, swelling agents, disintegrants, or other excipients, is then encapsulated in a porous wax matrix (described in detail herein). As noted, the wax in the matrix should be water insoluble, preferably having an initial melting point of at least 110 ℃ and a peak maximum melting point of at least 120 ℃, and preferably having a low melt viscosity, i.e., less than about 500 centipoise at a temperature within 25 ℃ above its melting point.
Fillers in the wax matrix may include inorganic salts (such as sodium or calcium sulphate), organic acids or salts thereof, clays, minerals (such as aluminosilicate, diatomaceous earth, talc), pigments (such as titanium dioxide), mono-or disaccharides (such as fructose, galactose and glucose or lactose, maltose, sucrose and trehalose), sugar alcohols (such as sorbitol or glycerol), cyclodextrins and polysaccharides (such as starch and maltodextrin or cellulose powders or gums (such as xanthan gum or sodium alginate)).
In some embodiments, the wax matrix includes optional water-soluble or water-insoluble fillers, pore formers, buffers, stabilizers, swelling agents, disintegrants, degradation-enhancing additives, or other excipients. The degradation-enhancing additive may promote wax degradation by different pathways, including photodegradation, thermal degradation, oxidative biodegradation, biodegradation via biofilm formation, or combinations thereof. An example of oxidative biodegradation additive technology is(Hoganas Add-X Biotechnology, Sweden (Add-X Biotech AB,
In order to encapsulate the enzyme in the wax matrix, the wax must first be heated until molten. The enzyme powder is dispersed within the molten wax along with any other excipients. The enzyme may be added before, after, or simultaneously with any excipients. The solid-liquid dispersion can be carried out batchwise or fed-batch in a stirred tank vessel or continuously in an in-line mixer. Once the enzyme is sufficiently dispersed to form a suspension in the molten wax, the wax suspension is atomized into particles. For example, a stream of molten suspension may be extruded or pumped onto a rotating disk atomizer. The formation of microencapsulated particles by rotary disc atomization is described, for example, in U.S. patent nos. 3,015,128, 4,256,677 and 6,001,387. Alternatively, wax microcapsules may be formed by other atomization methods, such as centrifugal extrusion (see, e.g., U.S. patent No. 4,386,895), vibrating nozzle atomization (see, e.g., WO 2012/098239), or jet cutting (see, e.g., DE 4,424,998 and U.S. patent No. 6,467,699), and then cooled to solidify the particles and collect the solidified particles.
In rotary disk atomization, the average particle size and particle size distribution of the final particles can be controlled by adjusting the rotational speed of the atomizing disk, taking into account the disk diameter, the flow rate of the suspension, and the viscosity and surface tension of the molten suspension. For a given disk apparatus, particle size is reduced by increasing the rotational speed of the disk, decreasing the feed rate of the molten suspension, and/or decreasing the viscosity and surface tension of the molten suspension.
To produce smaller, well-formed microparticles, it is preferred to use a melt suspension with a low melt viscosity. For example, to produce particles less than 500 microns, it is desirable to use a wax having a melt viscosity of less than 500 centipoise at a temperature within 25 ℃ above the melting temperature of the wax.
Trwmp characteristics
The resulting TRWMP is a substantially spherical microparticle free of coating, said microparticle having an average diameter of less than about 500 microns and containing active enzyme in a payload of greater than 5% w/w. Specific characteristics of the wax matrix are described in detail herein.
In some embodiments, the encapsulated enzyme retains at least 70%, preferably at least 80%, and more preferably at least 90% or more of the original enzyme activity after exposure to a temperature of 95 ℃ for 30 seconds in a typical animal feed pelleting process. The activity retention is easily measured by comparing the activity of the enzyme going into fines production with the amount of activity in the final TRWMP. These and other aspects and embodiments of the compositions and methods of the invention will be apparent to the skilled person in view of the present description. The following examples are intended to further illustrate, but not limit, the compositions and methods.
Examples of the invention
EXAMPLE 1 thermal analysis of polymeric and non-polymeric waxes
Thermal analysis of commercial fischer-tropsch wax, polyethylene wax, zinc stearate and stearic acid was performed by Differential Scanning Calorimetry (DSC) in a nitrogen atmosphere on a TA instruments DSC Q2000 thermal analyzer.
Samples of F-T and PE wax were incubated at 10 ℃ for min-1Is heated from 20 c to 180 c and cooled to 20 c at the same rate in the first scan. Then they were heated at 2 ℃ for min-1Is heated to 180 c and cooled to 20 c at the same rate in the second scan. Samples of zinc stearate and zinc stearate were incubated at 10 ℃ for min-1At a heating rate of from 20 ℃ to 160 ℃ and in the firstThe cooling to 20 ℃ was done at the same rate in the second scan. Then they were heated at 5 ℃ for min-1Was heated to 160 ℃ and cooled to 20 ℃ in a second scan at the same rate. Thermal properties such as the onset melting point, maximum peak and area under the heat flow curve (W/g vs c) were determined from the heating cycle of the second scan. The area under the heat flow curve (AUC) becomes proportional to the total enthalpy of the sample during heating between the initial and final temperatures of the DSC scan. The change in enthalpy with time (T), temperature (T) or scan rate (dT/dT) depends on the molecular mass uniformity of the wax.
Including an initial melting point, a maximum peak value and an Enthalpy Change Ratio (ECR) between 40 ℃ and 140 ℃(40,140)) The DSC thermograms of (A) are shown in FIGS. 1 to 5. Waxes suitable for use in the compositions and methods of the present invention are waxes having an ECR of less than 20%, preferably less than 15%, and more preferably less than 10%(40,140)Those of (a). Preferred waxes have an initial melting point and a maximum peak point above 100 ℃ and 120 ℃, respectively.
EXAMPLE 2 preparation of enzyme powder by spray drying
This example provides a general description of materials and methods for producing enzyme powders by spray drying. The spray-dried enzyme powder was prepared by spray drying in a Niro P-6.3 spray dryer equipped with a rotary atomizer configured in co-current mode (GEA Process Engineering a/S,
TABLE 2 typical spray drying Process conditions for the production of enzyme powders
The particle size distribution of the enzyme powder was analyzed by a laser diffraction method. D corresponding to 10%, 50% and 90% points on the cumulative volume-size distribution curve, respectively10、d50(median value) and d90Within a narrow range. For the phytase powder samples listed in examples 4-7 below, d10In the range of 11-14 μm, d50In the range of 25-39 μm, and d90The range is 53-105 μm.
EXAMPLE 3 production of enzyme granules by Hot melt Rotary disc atomization
As in the laboratory setup shown in fig. 6, enzyme granules to be described in the examples below were produced by using a rotary disc atomizer. First a wax substance (meltable carrier) is heated to melting in a glass container. The molten wax is further heated and maintained at a temperature of 15 deg.C to 30 deg.C above the melting point. The inactive ingredients and then the active spray-dried enzyme powder produced as described in example 2 were dispersed in the molten wax while stirring manually. The inactive ingredients are selected from the group consisting of fillers, binders, stabilizers, disintegrants, surfactants, osmolytes (osmolytes), pH modifiers and mixtures thereof. Table 3 provides a list of exemplary inactive excipients, their manufacturers/suppliers and their melting points for use in exemplary compositions.
TABLE 3 list of exemplary inactive excipients
The molten dispersion was homogenized by using a high shear homogenizer to ensure that a consistent lump-free dispersion was obtained. The molten dispersion was then dispensed onto a heated rotating stainless steel disc (10cm diameter) for atomization, either manually or using a peristaltic pump at a steady rate. The discs were mounted about 4.6 meters above the ground and operated at about 1500 to 6500rpm using a hydraulic pump. The fine melt droplets formed by atomization solidify into particles at room temperature. The particles were collected manually and stored in sealed plastic containers at room temperature.
The whole melt processing time is less than 2.5-5min, and comprises mixing materials and feeding rotary discs. Atomization of the melt formulation was carried out under normal ambient chamber conditions in a closed chamber of about 80 cubic meters.
EXAMPLE 4 production of Phytase granules consisting of spray-dried enzyme powder and Low-melting wax as matrix Material by Hot-melt Rotary disc atomization
The following are comparative examples of enzyme formulations made using low melting point carriers that do not meet the pelleting stability requirements as described in example 10.
The phytase fine-particle formulation was produced using the rotary disc atomization method described in example 3. The hot melt composition was prepared by adding the spray-dried phytase powder prepared as described in example 1 and calcium carbonate to the molten wax. The processing time was approximately 5min, including mixing the materials and dispensing the melt formulation onto a rotating disk. The fine melt droplets formed by atomization solidify rapidly into particles at room temperature. The particles were collected and stored in a sealed plastic container. Table 4 provides the composition of the phytase granule formulations. Since the stearate is dissolved in the molten stearic acid, a melt composition containing calcium stearate and sodium stearate is prepared at 90-110 ℃.
TABLE 4 composition of phytase produced with hot melt rotary disc atomization and low melting wax fines (% w/w)
EXAMPLE 5 production of Phytase granules consisting of spray-dried enzyme powder and high-melting wax as matrix Material by Hot-melt Rotary disc atomization
The following are examples of enzyme formulations with high melting point carriers that meet the pelleting stability requirements as described in example 11 according to their ECR values.
The phytase fine-particle formulation was produced using the rotary disc atomization method described in example 3. The hot melt composition was prepared by adding the spray-dried phytase powder prepared as described in example 1 and calcium carbonate to a molten wax at about 152 ℃. The processing time is less than 2.5min, including mixing the materials and dispensing the melt formulation onto a rotating disk. The fine melt droplets formed by atomization solidify rapidly into particles at room temperature. The particles were collected and stored in a sealed plastic container. Table 5 provides the composition of the phytase granule formulations.
TABLE 5 composition of phytase produced with hot melt rotary disc atomization and high melting wax fines (% w/w)
Example 6 production of phytase granules consisting of spray-dried enzyme powder and (low-melting) stearic acid and (high-melting) zinc stearate as matrix materials by hot-melt rotary disk atomization the following are comparative examples of enzyme formulations as described in example 5 of international patent application WO 03056934 a2 (assigned to Cargill, entitled "encapsulation by coating with a mixture of lipids and hydrophobic high-melting compounds"), indicating that these earlier formulations do not meet the granulation stability of the present invention.
The phytase fine-particle formulation was produced using the rotary disc atomization method described in example 3. Stearic acid (m.p.73 ℃ C.) andSMS Veg Zinc stearate (m.p.121 ℃ C.) was used as matrix material. The hot melt composition was prepared by adding a spray dried phytase powder to a molten wax formulation at about 152 ℃, wherein the stearic acid/zinc stearate ratio was 9:1 on a weight/weight basis. The melt formulation was transferred manually and stably as a single stream onto a rotating disk. MachiningThe time was approximately 1.3min, including mixing the materials and feeding the rotating discs. The fine melt droplets formed by atomization solidify rapidly into particles at room temperature. The particles were collected and stored in a sealed plastic container. Table 6 provides the composition of the phytase granule formulations.
TABLE 6 composition of phytase granules produced by Hot melt Rotary disc atomization (% w/w)
EXAMPLE 7 production of Phytase granules consisting of spray-dried enzyme powder and Zinc stearate and Polyterpene resin as high-melting matrix Material by Hot-melt Rotary disc atomization
The phytase fine-particle formulation was produced using the rotary disc atomization method described in example 3.SPVEG zinc stearate (m.p.121 ℃ C.), C125 (softening point 125 ℃ C.) anda135 Plus (softening point 135 ℃ C.) was used as matrix material. The hot melt composition is prepared by adding a spray-dried phytase powder to a molten wax formulation at about 152 ℃. The melt formulation was transferred manually and stably as a single stream onto a rotating disk. The processing time is approximately 1-1.5min, including mixing the materials and feeding the rotating discs. The fine melt droplets formed by atomization solidify rapidly into particles at room temperature. The particles were collected and stored in a sealed plastic container. Table 7 provides the composition of the phytase granule formulations.
TABLE 7 composition of phytase granules produced by Hot melt Rotary disc atomization (% w/w)
Example 8 procedure for steam Conditioning of animal feed containing enzyme granules
The thermal stability of the enzyme granules was evaluated in a minimill feed mill with a nominal pelleting capacity of 300 kg/h. The conditioning is performed at different controlled temperatures (e.g. 90 ℃ and 95 ℃). The production of the feed mixture, mixing technique, standing time, volume and cooling time were the same for all formulations. Only the addition of enzyme and the addition of steam in the cascade mixer were varied to achieve the desired conditioning temperature.
The feed grinder consists of: a horizontal mixer having a volumetric capacity of 700L and a mixing capacity of 80-300kg, operating at a speed of 48 rpm; a variable speed Skjold TR type dosing screw (for emptying the mixer and for dosing the feed); a KAHL type cascade mixer, 130cm x 30 cm-long x diameter, with 37 adjustable trays, running at a speed of 155rpm (residence time in the cascade mixer is estimated to be approximately 30 seconds based on a production rate of 300 kg/h); a collecting manifold installed at one side of the cascade mixer, having a drainer and 3 steam valves from which steam is added to the feed; and a high-pressure boiler of the Dan Stroke type with a maximum capacity of 400 kg steam/hour.
Steam was added to the feed and the addition of steam to the cascade mixer was controlled by an expansion valve. Three valves on the collection manifold are used to fine tune the desired temperature in the feed. For the addition of 1% steam, the temperature of the feed was increased by 14 ℃. The temperature of the meal (meal) was recorded with a digital thermometer of the type Testo 925 with a
The granulator used was a Simon Heesen of the Labor Monoroll type with a 7.5kW motor. In the case of a 3mm x 35mm (aperture x channel length) die, the inner diameter of the matrix is 173 mm. The height and diameter of the press are 50mm and 140mm respectively. The samples were cooled in a zoned cooling box with a perforated bottom, through a cooling tube with 1500m3Air/hourAnd a volume ventilator is used for cooling the coarse fodder through the subarea cooling box.
The formulation of the feed mixture corresponds to a conventional standard corn diet as shown in table 17. A sufficient amount of feed mixture was prepared in each experiment. This base mixture was produced in one go in a mill and mixing device and stored in a container before each test. A feed "premix" was prepared by blending a given amount of enzyme granules with 10kg of the feed mixture in a 70L forced mixer operating at 45rpm for 10 min. The premix is then added to about 110kg of feed mixture in the horizontal mixer of the feed mill and mixed for 10 minutes to produce a "test feed" or "meal" (mash). In the case of phytase, a sufficient amount of phytase fines is added to the premix to produce the target enzyme activity of 5,000FTU/kg of test feed. A "pre-steam" sample was collected from the test feed prior to pelleting and stored in a labeled container at normal ambient temperature until enzyme activity was analyzed.
A reference phytase granule product with known phytase activity (acting as a control) was added as a control at 5,000FTU/kg of test feed in all pelleting tests.
TABLE 8 composition of standard corn feed in pelleting test
Composition (I)
Weight percent of
Corn (corn)
61.10
Soybean powder
48
31.43％
Soybean oil
4.00％
Salt (salt)
0.40％
DL-methionine
0.20％
Limestone
1.16％
Calcium hydrogen phosphate
1.46％
Vitamin/mineral premix
0.25％
Total of
100.00％
The test feed was pelletised in a Simon Heesen granulator with a die. The capacity was set at 300kg/h and adjusted according to the dosing screw. In the cascade mixer, the feed is heated by steam to the target outlet (or discharge) temperatures of 90 ℃ and 95 ℃. The amount of steam is regulated by a pressure reducing valve and a manifold. The "post-steam" sample was collected as an approximately 0.5kg subsample, which was removed and placed in a cooling box 10-15 seconds immediately after the pellets had left the pelletizer. For each temperature level, the first subsample was taken at the time of establishing the operation after 8-10min of granulation. Sub-samples were collected over a period of 1-1.5min, which corresponds to 5-7.5kg of pelleted feed. All samples were aerated and cooled at ambient temperature for 15 minutes, which ensured the removal of the remaining heat from the pellets. The post-steamed samples were stored in labeled containers at normal ambient temperature until assayed for enzyme activity.
Before the meal mixture is produced in the mill and the mixing device, the feed mill is cleaned of feed residues and the mixer is vacuum cleaned. The micro feed grinder was cleaned before and after each trial. The mixer and dosing device were vacuum cleaned and the cascade mixer was self-emptying. After each trial, the mini-mixer and cooling tank for the premix was thoroughly cleaned.
EXAMPLE 9 analysis of Phytase Activity of feed samples
An internal assay was developed to accurately analyze the activity of trichoderma reesei (t. reesei) phytase in animal feed and in premixes containing phytase fines when mixed into feed. Said method IS very similar to the harmonized standard method IS 030024: 2009 (i.e. ISO 30024: Determination of Animal feed-Phytase Activity, 2009) and follows the same principle, i.e. incubation of Phytase with sodium phytate, which results in the release of inorganic phosphate. Inorganic phosphates produce yellow complexes when reacted with molybdate-vanadate reagents. The optical density of the yellow complex was measured at a wavelength of 415 nm. The degree of color formation can be directly related to the enzyme activity. Quantification of activity was performed by absolute methods using a phosphate standard calibration curve.
This method was developed according to the principles set forth in ISO 9001 (i.e., ISO 9001: 2008 Quality management systems) and Good Laboratory Practice (Good Laboratory Practice), and has been developed according to ISO 78-2: written according to the rules given in 1999 (i.e. ISO 78-2: format of Chemistry-Standard-Part 2: Methods of Chemical Analysis, 1999).
Phytase Activity Unit (FTU) is defined as the amount of enzyme that releases 1. mu. mol of inorganic orthophosphate from sodium phytate substrate per minute at pH 5.5 and 37 ℃. A sample of ground feed with known phytase activity (5,000FTU/kg) was used as a control.
EXAMPLE 10 steam-regulated thermal stability of granular Phytase to animal feed containing Phytase granules made from Low melting wax as matrix Material
The following are comparative examples illustrating that the enzyme formulation with low melting point carrier described in example 4 does not meet the pelleting stability requirements of the present invention.
The phytase granules of example 4 were evaluated in animal feed pelleting trials according to the procedures described in examples 8 and 9. The particle size ranges of the test formulations are shown in table 9.
TABLE 9 particle size distribution (% w/w) of phytase granule formulations evaluated in pelleting tests
Formulations
Particle size range
P2
212-300μm
P4
212-300μm
P44
212-300μm
P46
212-300μm
P54
212-300μm
The enzyme activity of the phytase granule formulation measured in the feed meal before steam processing and the relative residual activity after steam processing are shown in table 10. All phytase formulations made with low-melting waxes as matrix material lost at least 85% of their initial enzymatic activity (n ═ 2, avg ± std dev) during steam pelleting.
TABLE 10 enzymatic Activity of Phytase granules produced by Hot melt Rotary disc atomization
Formulations
Initial Activity (FTU/g)
Relative residual Activity (%)
Relative residual Activity (%)
90℃
95℃
P2
30160±1450
8.1％±1.8％
4.8％±1.7％
P4
32084±1040
6.8％±1.0％
5.2％±0.5％
P44
20234±558
14.8％±2.4％
5.1％±2.9％
P46
19608±1038
7.7％±0.8％
6.5％±1.0％
P54
12990±1810
8.4％±2.2％
7.8％±2.1％
Example 11 steam-regulated thermal stability of granular Phytase to animal feed containing Phytase granules made from high melting wax as matrix Material
The following is an example illustrating the enzyme formulation described in example 5 with a high melting point carrier that meets the pelleting stability requirements of the invention. The phytase granules of example 5 were evaluated in animal feed pelleting trials according to the procedures described in examples 9 and 10. The particle size ranges of the test formulations are shown in table 11.
TABLE 11 particle size range (% wt/wt) of phytase granule formulations evaluated in pelleting tests
Formulations
Particle size range
P40.4
212-425μm
P58.1
212-300μm
P96.1
212-300μm
P97.6
212-300μm
P97.2
212-300μm
The enzyme activity of the phytase granule formulations measured in the feed meal before steam processing and the relative residual activity after steam processing are shown in table 12. All phytase formulations made with high melting point waxes as matrix material retained at least 50% of their initial enzyme activity during steam pelleting. After granulation at 95 ℃ with an ECR of 6.1% (40,140)The high melting point waxes of (a) maintain at least 85% of their initial activity (n ═ 2, avg ± stddev).
TABLE 12 enzymatic Activity of Phytase granules produced by Hot melt Rotary disc atomization
Formulations
Initial Activity (FTU/g)
Relative residual Activity (%)
Relative residual Activity (%)
90℃
95℃
P40.4
10979±98
54.7％±5.2％
51.3％±9.4％
P58.1
17800±148
74.4％±1.1％
68.8％±5.4％
P96.1
29852±2176
89.5％±8.4％
86.1％±6.6％
P97.6
21604±704
102.4％±16.8％
84.9％±3.6％
P97.2
31744±4032
96.4％±24.3％
100.2％±14.6％
Example 12 steam-regulated thermal stability of granular Phytase to animal feed containing Phytase granules made from stearic acid and Zinc stearate, and Zinc stearate and Polyterpene resins
The following are examples illustrating the performance of the phytase granules of examples 6 and 7 as evaluated in animal feed pelleting trials according to the procedures described in examples 8 and 9. The particle size ranges of the test formulations are shown in table 13.
TABLE 13 particle size distribution (% wt/wt) of phytase granule formulations evaluated in pelleting tests
The enzyme activity of the phytase granule formulations measured in the feed meal before steam processing and the relative residual activity after steam processing are shown in table 14. The phytase formulation P166.4 containing low melting stearic acid (as described in WO03056934 a 2) lost all its initial enzymatic activity during the granulation process. In comparison with formulation P166.1, which is prepared using only zinc stearate as matrix material, with high-melting zinc stearate Resin-made phytase formulations P170.2 and P171.3 showed improved pelleting stability (n ═ 2, avg ± std dev).
TABLE 14 enzymatic Activity of Phytase granules produced by Hot melt Rotary disc atomization
Examples 13 and 14 describe bioavailability studies on broiler chickens and pigs to assess the biological efficacy of phytase granule formulations of the invention compared to commercial products.
Example 13: biological efficacy of polyethylene wax micro-encapsulated phytase granules in broiler chickens
Three separate in vivo studies ("a", "B" and "C") were conducted to evaluate and compare the biological efficacy of phytase granule formulations produced using hot melt rotary disc atomization as described in example 3. Three formulations P75.1M and P75.4M, P96.5 were microencapsulated in Polyethylene (PE) homopolymer wax POLYWAXTMComposition of spray-dried phytase in 2000 (table 15). Bioefficacy of PE wax microencapsulated Phytase granules with commercial DaniscoThe biological efficacy of the PHY products (phytase variants from Buttiauxella sp.) was compared. Studies A and B relate to formulations P75.1M, P75.4M and
TABLE 15 composition of phytase granules produced by Hot melt Rotary disc atomization (% w/w)
TABLE 16 Experimental design for study A and B
TABLE 17 Experimental design for study C
One day old Ross 708 male broiler chickens were used in all studies. At the beginning of the study, 8 birds were randomly assigned to the shelving cages according to the respective treatments performed by zoning. Only healthy birds were selected for the experiment and none were changed throughout the study.
Bird weights were recorded at study start (day 0), day 7 and study termination (day 14). The cage is the experimental unit. The diet was fed in a meal format and was formulated to meet or exceed NRC (national research council) standards, except for Ca and AvP (table 18). All feeds were mixed using a Davis S-20 mixer (h.c. Davis Sons Manufacturing co., Bonner Springs, KS, USA, bannss, bannspels, kansas). The mixer was flushed between each treatment to prevent cross-contamination between the rations. Samples were collected from each treatment diet at the beginning, middle, and end of each batch and chopped together for analysis of enzyme activity in the diet.
All birds were fed corn soybean basal diet until day 7; the treated food was fed from day 7 onwards. At feed change, the feeder is removed from the cage, weighed back, emptied, and refilled with the appropriate treatment diet. On the last day of the study, the feed was weighed.
TABLE 18 diet formulations
Composition (I)
Initial (0-7 days) content (%)
NC (7-14 days) content (%)
Corn (corn)
52.09
58.27
42.53
37.56
Pig/poultry fat
1.32
1.62
L-lysine HCl
0.12
0.056
DL-methionine
0.30
0.24
L-threonine
0.039
0.0025
Salt (salt)
0.32
0.32
Limestone
1.11
1.37
Calcium hydrogen phosphate
1.68
0.061
Vit/TE for poultry
0.5
0.5
Met energy
12.13
12.55
Crude protein
25
23
Calcium carbonate
1
0.7
Non-phytic acid p(nPP)
0.45
0.15
Na
0.16
0.16
Cl
0.25
0.24
Avail Lys
1.27
1.1
Avail Met+Cys
0.94
0.84
Avail Thr
0.83
0.73
Avail Trp
0.26
0.24
At the termination of the study, six birds/cage (two birds of average weight, two birds below average weight and two birds above average weight) were selected for bone ash measurements. The right tibia of each bird was removed. The bone was dried at 100 ℃ overnight, divided into three equal parts, the two end parts (epiphyses) were weighed together and the middle part was weighed in a separate crucible, and then cremated in a muffle furnace at 600 ℃ for 16 hours. Ash is then expressed as a percentage (as a proportion of dry bone weight) based on the weight of reaming ash (reaming ash). Epiphyseal ash and mid-bone ash are added together to enable the calculation of the entire tibial ash. For phalangeal ash measurements, all birds/cages were used, the middle toe was taken, split distal to proximal of the third phalanx, the toes were merged on a fence (pen) basis, and ashed in a separate crucible from those with the tibia. Data were analyzed using ANOVA and mean value separation was performed to test differences between different enzyme formulations and enzyme dosages. Cages were used as experimental units.
Figures 7-9 show the change in tibial epiphyseal ash, total tibial ash and phalangeal ash in study a, respectively, as a function of the measured feed phytase activity. The results obtained for tibial epiphyseal ash, total tibial ash and phalangeal ash indicate that the formulations of the invention are compatible with commercial processesThere was no significant difference in bioavailability of the enzyme between PHY products. Phytase has a significant effect on the bone ash, whereby higher enzyme content levels result in higher bone ash.
Figures 10-12 show the change in tibial epiphyseal ash, total tibial ash and phalangeal ash in study B, respectively, as a function of measured feed phytase activity. The results obtained for the tibial epiphyseal ash and the total tibial ash indicate that there are significant differences in the bioavailability of the enzyme between the different formulations, and therefore, compared to commercial productsCompared to PHY products, P75.1M and P75.4M showed higher bioavailability levels. Formulations P75.1M, P75.4M andthere was no significant difference in enzyme bioavailability between PHYs. Phytase has a significant effect on the bone ash, whereby higher enzyme content levels result in higher bone ash.
Figures 13-15 show the change in tibial epiphyseal ash, total tibial ash and phalangeal ash in study C, respectively, as a function of measured feed phytase activity. Tibial epiphyseal ash, whole Results obtained with tibial and phalangeal ashes indicated that formulations P75.1M, P96.5 and
Example 14 Bioefficacy Studies of polyethylene wax microencapsulated Phytase Fine particles in pigs
An in vivo study was conducted to evaluate and compare the biological efficacy of phytase granule formulations P75.1M and P75.4M, which were produced using hot melt rotary disc atomization (see example 13). Bioefficiency and commercialization of PE wax microencapsulated Phytase granulesThe biological efficacy of the PHY products was compared.
A total of 70 pigs (16.82 ± 1.34kg initial BW) were assigned to a randomized complete block design with 7 diets and 10 duplicate pigs/diets and two time periods. Control diets were formulated with corn and soybean meal (SBM) and no phytase was added to this diet. Six diets were similar to the control diet except that the diet contained phytase (table 19). The diet was fed in a meal format and was formulated to meet or exceed NRC (national research council) standards, except for Ca and AvP (table 20).
TABLE 19 Experimental design for study HB1304
TABLE 20 diet formulations
At each time period, after 5 days of acclimation, fecal samples were collected on days 6-12 and analyzed for phosphorus (P) using the total collection method. To supply energy every dayPigs were fed with 3-fold maintenance demand (i.e. 197kcal ME/kg BW)0.60(ii) a NRC, 2012) divided into two equal meals. Water was always available throughout the experiment. The weight of the pigs was recorded at the beginning of the acclimation period (day 0) and at the end of each collection period (day 13). The amount of feed supplied per day during the collection period was also recorded.
The beginning and end of stool collection was marked by the addition of a non-digestible marker. At the end of the experiment, the fecal samples were dried in a forced air oven and finely ground prior to analysis. P was analyzed in diet, ingredients and fecal samples and the apparent total digestive tract digestibility (ATTD)% of P was calculated from the following equation: ATTD P (%) - [ (Pin-Pfo)/Pi ] x 100, where Pi is the total uptake of P from
As shown in FIG. 16, the enzyme had a significant effect on the apparent total digestive tract digestibility (ATTD P%) of P, whereby P75.4M showed a ratio of P75.1M to P75.1M and commercial availabilityThe higher ATTD P% of the PHY product indicates a higher bioavailability level of formulation P75.4M.
Based on the results of examples 13 and 14, it is evident that the performance of the high melting point PE wax compositions in terms of the bioavailability marker studied is in all cases equal to or greater than that of the commercial onePHY products.
- 上一篇：一种医用注射器针头装配设备
- 下一篇：非洲猪瘟病毒和经典猪瘟病毒的化学缓疫